莫西沙星与左氧氟沙星治疗社区获得性肺炎的随机对照研究  

Randomized controlled clinical trial of moxifloxacin versus levofloxacin in the treatment of community acquired pneumonia

作　　者：杨惠芬[1] 刘德梦[1] 朱宁[1] 王哲[1] 宋诗铎[1] 胡文芝[1] 

机构地区：[1]天津医科大学第二医院感染科,天津300211

出　　处：《中国抗生素杂志》2009年第11期703-704,I0001,I0002,共4页Chinese Journal of Antibiotics

摘　　要：目的评价莫西沙星注射液与左氧氟沙星注射液在治疗社区获得性肺炎中的临床疗效和安全性。方法采用区组随机、开放、阳性药物对照的研究方法。结果治疗结束后d7,PP分析:试验组和对照组的临床有效率分别为97.0%和92.1%;细菌清除率:PP/MBE分析两组分别为96.0%和96.7%。安全性分析:试验组和对照组的不良反应发生率均为20%。上述结果经统计学检验两组比较均无显著性差异(P>0.05)。结论莫西沙星注射液和左氧氟沙星注射液治疗社区获得性肺炎安全、有效。Objective To evaluate the efficacy and safety of moxifloxacin for the treatment of the patients with community acquired pneumonia. Methods A randomized controlled, parallel, block, open clinical trial was conducted. Patients were randomly divided into groups. Results The overall efficacy rates in PP were 97.0% and 92.1% , respectively. The bacterial eradication rates of each group in PP/MBE were 96.0% and 96.7% , respectively. The adverse drug reaction rates, which related to study drug of each group were 20%. The results showed that there were no statistical differences between these two groups （ P 〉 0.05 ）. Conclusion Moxifloxacin was effective and safe as levofloxacin in the treatment of community acquired pneumonia.

关 键 词：莫西沙星 左氧氟沙星 社区获得性肺炎 随机对照研究 

分 类 号：R978.19[医药卫生—药品]